Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Histotype-specific analysis of acid ceramidase expression in ovarian cancer.

El-Balat A, Karn T, Holtrich U, Becker S, Kommoss S, Győrffy B, Anglesio MS, Huntsman DG, Drosos Z, Rody A, Gevensleben H, Hanker LC.

Virchows Arch. 2020 Jan 2. doi: 10.1007/s00428-019-02728-0. [Epub ahead of print]

PMID:
31897818
2.

Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2020 Jan 1;26(1):213-219. doi: 10.1158/1078-0432.CCR-19-1741. Epub 2019 Sep 16.

PMID:
31527166
3.

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P.

Gynecol Oncol. 2019 Nov;155(2):186-191. doi: 10.1016/j.ygyno.2019.08.024. Epub 2019 Sep 10.

4.

Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study.

Klapdor R, Wölber L, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Jückstock J, Hilpert F, de Gregorio N, Hillemanns P, Fürst ST, Mahner S.

Gynecol Oncol. 2019 Sep;154(3):565-570. doi: 10.1016/j.ygyno.2019.06.013. Epub 2019 Jun 18.

PMID:
31227222
5.

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).

Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.

J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.

PMID:
30979843
6.

Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A.

Gynecol Oncol. 2019 Feb;152(2):235-242. doi: 10.1016/j.ygyno.2018.11.008. Epub 2018 Nov 20.

PMID:
30466805
7.

What is the evidence for lymphadenectomy in presumed early ovarian cancer?

Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. No abstract available.

PMID:
30374648
8.

Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients.

El-Balat A, Schmeil I, Karn T, Holtrich U, Mavrova-Risteska L, Rody A, Youssef A, Hanker LC.

In Vivo. 2018 Sep-Oct;32(5):1275-1281. doi: 10.21873/invivo.11377.

9.

Claudin-1 expression in cervical cancer.

Hoellen F, Waldmann A, Banz-Jansen C, Holtrich U, Karn T, Oberländer M, Habermann JK, Hörmann M, Köster F, Ribbat-Idel J, Thill M, Rody A, El-Balat A, Hanker L.

Mol Clin Oncol. 2017 Nov;7(5):880-884. doi: 10.3892/mco.2017.1391. Epub 2017 Aug 25.

10.

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).

Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.

PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.

11.

Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L, Klare P, Abenhardt W, Nedkova Y, Yalcinkaya I, Heinrich G, Sommer H, Mahner S, Wimberger P, Koensgen-Mustea D, Richter R, Oskay-Oezcelik G, Sehouli J; Ovarian Cancer Study Group of the North-Eastern German Society of Gynaecological Oncology (NOGGO).

Gynecol Oncol Res Pract. 2017 Mar 7;4:6. doi: 10.1186/s40661-017-0040-2. eCollection 2017.

12.

Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study.

Klapdor R, Hillemanns P, Wölber L, Jückstock J, Hilpert F, de Gregorio N, Iborra S, Sehouli J, Habermann A, Fürst ST, Strauß HG, Baumann K, Thiel F, Mustea A, Meier W, Harter P, Wimberger P, Hanker L, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Jäger M, Mahner S.

Ann Surg Oncol. 2017 May;24(5):1314-1321. doi: 10.1245/s10434-016-5687-0. Epub 2016 Nov 28.

PMID:
27896515
13.

Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gynäkologische Onkologie CaRE-1 multicenter study.

Woelber L, Griebel LF, Eulenburg C, Sehouli J, Jueckstock J, Hilpert F, de Gregorio N, Hasenburg A, Ignatov A, Hillemanns P, Fuerst S, Strauss HG, Baumann KH, Thiel FC, Mustea A, Meier W, Harter P, Wimberger P, Hanker LC, Schmalfeldt B, Canzler U, Fehm T, Luyten A, Hellriegel M, Kosse J, Heiss C, Hantschmann P, Mallmann P, Tanner B, Pfisterer J, Richter B, Neuser P, Mahner S.

Eur J Cancer. 2016 Dec;69:180-188. doi: 10.1016/j.ejca.2016.09.038. Epub 2016 Nov 10.

PMID:
27837710
14.

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26.

PMID:
27789470
15.

Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7).

Harter P, Sehouli J, Reuss A, Baumann K, Hanker L, Kimmig R, Schröder W, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Canzler U, Lück HJ, Meier W, Fehm T, du Bois A.

Int J Gynecol Cancer. 2016 Nov;26(9):1636-1641.

PMID:
27654266
16.

Trefoil factor 3 expression in epithelial ovarian cancer exerts a minor effect on clinicopathological parameters.

Hoellen F, Kostara A, Karn T, Holtrich U, El-Balat A, Otto M, Rody A, Hanker LC.

Mol Clin Oncol. 2016 Oct;5(4):422-428. Epub 2016 Aug 17.

17.

Corrigendum to "Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group" [Eur J Cancer 49 (2013) 1905-1914].

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S.

Eur J Cancer. 2016 Sep;65:192-193. doi: 10.1016/j.ejca.2016.06.014. Epub 2016 Jul 25. No abstract available.

PMID:
27468640
18.

Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.

Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E.

Gynecol Oncol. 2016 Sep;142(3):465-70. doi: 10.1016/j.ygyno.2016.05.011. Epub 2016 Jun 25.

PMID:
27184721
19.

Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).

Emons G, Kurzeder C, Schmalfeldt B, Neuser P, de Gregorio N, Pfisterer J, Park-Simon TW, Mahner S, Schröder W, Lück HJ, Heubner ML, Hanker L, Thiel F, Hilpert F.

Gynecol Oncol. 2016 Mar;140(3):450-6. doi: 10.1016/j.ygyno.2015.12.025. Epub 2015 Dec 28.

PMID:
26731724
20.

The prognostic impact of age in different molecular subtypes of breast cancer.

Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls EB, Lausen K, Hanker L, Holtrich U, Becker S, Karn T.

Breast Cancer Res Treat. 2015 Aug;152(3):667-73. doi: 10.1007/s10549-015-3491-3. Epub 2015 Jul 21.

PMID:
26195120
21.

The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.

Fotopoulou C, Sehouli J, Ewald-Riegler N, de Gregorio N, Reuss A, Richter R, Mahner S, Kommoss F, Schmalfeldt B, Fehm T, Hanker L, Wimberger P, Canzler U, Pfisterer J, Kommoss S, Hauptmann S, du Bois A; ROBOT investigators.

Int J Gynecol Cancer. 2015 Sep;25(7):1248-52. doi: 10.1097/IGC.0000000000000476.

PMID:
25978292
22.

Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study.

Trillsch F, Mahner S, Vettorazzi E, Woelber L, Reuss A, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Fotopoulou C, Schmalfeldt B, Burges A, Ewald-Riegler N, de Gregorio N, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Kommoss S, Kommoss F, Hauptmann S, du Bois A.

Br J Cancer. 2015 Feb 17;112(4):660-6. doi: 10.1038/bjc.2014.648. Epub 2015 Jan 6.

23.

Neonatal Transfer Rate and Mode of Delivery from 37th Week of Gestation in a German Perinatal Center Level 1.

Reinhard J, Hanker L, Sänger N, Yuan J, Louwen F.

Geburtshilfe Frauenheilkd. 2013 Apr;73(4):324-329.

24.

Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).

Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P.

Gynecol Oncol. 2014 Jun;133(3):427-32. doi: 10.1016/j.ygyno.2014.03.576. Epub 2014 Apr 5.

PMID:
24713545
25.

Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study.

Trillsch F, Mahner S, Woelber L, Vettorazzi E, Reuss A, Ewald-Riegler N, de Gregorio N, Fotopoulou C, Schmalfeldt B, Burges A, Hilpert F, Fehm T, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Baumann K, Keyver-Paik MD, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schroeder W, Muenstedt K, Richter B, Kommoss F, Hauptmann S, du Bois A.

Ann Oncol. 2014 Jul;25(7):1320-7. doi: 10.1093/annonc/mdu119. Epub 2014 Mar 11.

26.

The role of lymphadenectomy in uterine sarcoma: a clinical practical approach based on retrospective analysis.

Hoellen F, Waldmann A, Benthin S, Hanker L, Rody A, Fischer D.

Anticancer Res. 2014 Feb;34(2):985-93.

PMID:
24511044
27.

Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).

Emons G, Gorchev G, Harter P, Wimberger P, Stähle A, Hanker L, Hilpert F, Beckmann MW, Dall P, Gründker C, Sindermann H, Sehouli J.

Int J Gynecol Cancer. 2014 Feb;24(2):260-5. doi: 10.1097/IGC.0000000000000044.

28.

Signal quality of non-invasive fetal electrocardiogram in vaginal breech delivery: a case-controlled study.

Sänger N, Louwen F, Reinhard J, Yuan J, Hanker L.

Arch Gynecol Obstet. 2013 Nov;288(5):1017-20. doi: 10.1007/s00404-013-2860-6. Epub 2013 Apr 24.

PMID:
23612929
29.

Acid ceramidase (AC)--a key enzyme of sphingolipid metabolism--correlates with better prognosis in epithelial ovarian cancer.

Hanker LC, Karn T, Holtrich U, Gätje R, Rody A, Heinrich T, Ruckhäberle E, Engels K.

Int J Gynecol Pathol. 2013 May;32(3):249-57. doi: 10.1097/PGP.0b013e3182673982.

PMID:
23518908
30.

Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.

du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, Kommoss F, Schmalfeldt B, Hilpert F, Fehm T, Burges A, Meier W, Hillemanns P, Hanker L, Hasenburg A, Strauss HG, Hellriegel M, Wimberger P, Keyver-Paik MD, Baumann K, Canzler U, Wollschlaeger K, Forner D, Pfisterer J, Schröder W, Münstedt K, Richter B, Kommoss S, Hauptmann S; Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.

Eur J Cancer. 2013 May;49(8):1905-14. doi: 10.1016/j.ejca.2013.01.035. Epub 2013 Mar 13.

PMID:
23490647
31.

Prognostic impact of fascin-1 (FSCN1) in epithelial ovarian cancer.

Hanker LC, Karn T, Holtrich U, Graeser M, Becker S, Reinhard J, Ruckhäberle E, Gevensleben H, Rody A.

Anticancer Res. 2013 Feb;33(2):371-7.

PMID:
23393326
32.
33.

Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes.

Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T.

Breast Cancer Res Treat. 2013 Jan;137(2):407-16. doi: 10.1007/s10549-012-2356-2. Epub 2012 Dec 16.

PMID:
23242614
34.

Delivery mode and neonatal outcome after a trial of external cephalic version (ECV): a prospective trial of vaginal breech versus cephalic delivery.

Reinhard J, Sänger N, Hanker L, Reichenbach L, Yuan J, Herrmann E, Louwen F.

Arch Gynecol Obstet. 2013 Apr;287(4):663-8. doi: 10.1007/s00404-012-2639-1. Epub 2012 Nov 25.

PMID:
23183715
35.

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.

Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; AGO and GINECO study group.

Ann Oncol. 2012 Oct;23(10):2605-12. Epub 2012 Aug 21.

PMID:
22910840
36.

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.

Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, Kurzeder C, Hilpert F, Hasenburg A, Canzler U, Hanker LC, Hillemanns P, Richter B, Wollschlaeger K, Dewitz T, Bauerschlag D, Wagner U.

Ann Oncol. 2012 Sep;23(9):2265-71. doi: 10.1093/annonc/mds003. Epub 2012 Feb 29.

PMID:
22377563
37.

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.

Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S.

Ann Oncol. 2012 Sep;23(9):2259-64. doi: 10.1093/annonc/mdr628. Epub 2012 Feb 21.

38.

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.

Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, Müller V, Solbach C, Gaetje R, Hanker L, Ahr A, Liedtke C, Ruckhäberle E, Kaufmann M, Rody A.

PLoS One. 2011;6(12):e28403. doi: 10.1371/journal.pone.0028403. Epub 2011 Dec 29.

39.

A clinically relevant gene signature in triple negative and basal-like breast cancer.

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M.

Breast Cancer Res. 2011 Oct 6;13(5):R97. doi: 10.1186/bcr3035.

40.

Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.

Karn T, Pusztai L, Ruckhäberle E, Liedtke C, Müller V, Schmidt M, Metzler D, Wang J, Coombes KR, Gätje R, Hanker L, Solbach C, Ahr A, Holtrich U, Rody A, Kaufmann M.

Eur J Cancer. 2012 Jan;48(1):12-23. doi: 10.1016/j.ejca.2011.06.025. Epub 2011 Jul 7.

PMID:
21741824
41.

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A.

Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd.

PMID:
21270612
42.

Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.

Karn T, Ruckhäberle E, Hanker L, Müller V, Schmidt M, Solbach C, Gätje R, Gehrmann M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2011 Nov;130(2):409-20. doi: 10.1007/s10549-010-1333-x. Epub 2011 Jan 4.

PMID:
21203899
43.

SATB1 gene expression and breast cancer prognosis.

Hanker LC, Karn T, Mavrova-Risteska L, Ruckhäberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I.

Breast. 2011 Aug;20(4):309-13. doi: 10.1016/j.breast.2010.10.002. Epub 2010 Oct 25.

44.

Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.

Emons G, Kaufmann M, Gorchev G, Tsekova V, Gründker C, Günthert AR, Hanker LC, Velikova M, Sindermann H, Engel J, Schally AV.

Gynecol Oncol. 2010 Dec;119(3):457-61. doi: 10.1016/j.ygyno.2010.08.003. Epub 2010 Sep 9.

PMID:
20828803
45.

Breast Cancer Proteomics - Differences in Protein Expression between Estrogen Receptor-Positive and -Negative Tumors Identified by Tandem Mass Tag Technology.

Ruckhäberle E, Karn T, Hanker L, Schwarz J, Schulz-Knappe P, Kuhn K, Böhm G, Selzer S, Erhard N, Engels K, Holtrich U, Kaufmann M, Rody A.

Breast Care (Basel). 2010 Mar;5(1):7-10. Epub 2010 Feb 16.

46.

Prognostic impact of thymidine phosphorylase expression in breast cancer--comparison of microarray and immunohistochemical data.

Ruckhäberle E, Karn T, Engels K, Turley H, Hanker L, Müller V, Schmidt M, Ahr A, Gaetje R, Holtrich U, Kaufmann M, Rody A.

Eur J Cancer. 2010 Feb;46(3):549-57. doi: 10.1016/j.ejca.2009.11.020. Epub 2009 Dec 18.

PMID:
20022486
47.

Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.

Ruckhäberle E, Holtrich U, Engels K, Hanker L, Gätje R, Metzler D, Karn T, Kaufmann M, Rody A.

Climacteric. 2009 Dec;12(6):502-13. doi: 10.3109/13697130902939913.

PMID:
19905902
48.

Clinical relevance of the putative stem cell marker p63 in breast cancer.

Hanker L, Karn T, Ruckhaeberle E, Gaetje R, Solbach C, Schmidt M, Engels K, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Aug;122(3):765-75. doi: 10.1007/s10549-009-0608-6. Epub 2009 Nov 7.

PMID:
19898932
49.

Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer.

Karn T, Metzler D, Ruckhäberle E, Hanker L, Gätje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M, Rody A.

Breast Cancer Res Treat. 2010 Apr;120(3):567-79. doi: 10.1007/s10549-009-0416-z. Epub 2009 May 20.

PMID:
19455418
50.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.

Supplemental Content

Loading ...
Support Center